Staging Dementia Using Clinical Dementia Rating Scale Sum of Boxes Scores
2008/08/01 by Sid E. O’Bryant · 45 citations
Medicine · Health Professions · #Dementia and Cognitive Impairment Research #Balance, Gait, and Falls Prevention #Intracerebral and Subarachnoid Hemorrhage Research
paper · doi:10.1001/archneur.65.8.1091
Abstract
BACKGROUND: The Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) score is commonly used, although the utility regarding this score in staging dementia severity is not well established. OBJECTIVE: To investigate the effectiveness of CDR-SOB scores in staging dementia severity compared with the global CDR score. DESIGN: Retrospective study. SETTING: Texas Alzheimer's Research Consortium minimum data set cohort. PARTICIPANTS: A total of 1577 participants (110 controls, 202 patients with mild cognitive impairment, and 1265 patients with probable Alzheimer disease) were available for analysis. MAIN OUTCOME MEASURES: Receiver operating characteristic curves were generated from a derivation sample to determine optimal cutoff scores and ranges, which were then applied to the validation sample. RESULTS: Optimal ranges of CDR-SOB scores corresponding to the global CDR scores were 0.5 to 4.0 for a global score of 0.5, 4.5 to 9.0 for a global score of 1.0, 9.5 to 15.5 for a global score of 2.0, and 16.0 to 18.0 for a global score of 3.0. When applied to the validation sample, kappa scores ranged from 0.86 to 0.94 (P < .001 for all), with 93.0% of the participants falling within the new staging categories. CONCLUSIONS: The CDR-SOB score compares well with the global CDR score for dementia staging. Owing to the increased range of values, the CDR-SOB score offers several advantages over the global score, including increased utility in tracking changes within and between stages of dementia severity. Interpretive guidelines for CDR-SOB scores are provided.
Cited by
- A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
- Chronic pain in Alzheimer disease and the role of neuroimmune interactions
- Lewy body co‐pathology in Alzheimer's disease and primary age‐related tauopathy contributes to differential neuropathological, cognitive, and brain atrophy patterns
- Learning Patient-Specific Disease Dynamics with Latent Flow Matching for Longitudinal Imaging Generation
- Evaluating 18F-Florzolotau tau PET for Alzheimer’s disease diagnosis with 18F-Flortaucipir as reference
- Locus coeruleus integrity is related to tau burden and memory loss in autosomal-dominant Alzheimer's disease
- Predicting Mild Cognitive Impairment to Alzheimer's Disease Progression by Explainable Multi‐Modal Framework Using Deep and Machine Learning Hybrid Model
- The Relationship of Physical Function, Physical Resilience, and Physical Activity Among Recently Hospitalized Older Adults With Dementia
- Peripheral immune profiling in frontotemporal dementia
- Cognitive and neuropsychological trajectories in patients with mixed neurodegenerative pathologies
- Amygdala-predominant Lewy bodies associate with cognitive decline and amygdala atrophy in Alzheimer’s disease neuropathological change
- S-Chain: Structured Visual Chain-of-Thought For Medicine
- Disentangling Neurodegeneration with Brain Age Gap Prediction Models: A Graph Signal Processing Perspective
- SHAP-Based Supervised Clustering for Sample Classification and the Generalized Waterfall Plot
- On estimation in the nested case‐control design under nonproportional hazards
- Continuity, coping and finding meanings in everyday life: Storytelling by family members of people with young onset dementia
- Biological age acceleration in Alzheimer’s disease modulates relative cortical to medial temporal lobe neurodegeneration
- Improving Interpretability in Alzheimer's Prediction via Joint Learning of ADAS-Cog Scores
- A Weighted Vision Transformer-Based Multi-Task Learning Framework for Predicting ADAS-Cog Scores
- Flexible Multimodal Neuroimaging Fusion for Alzheimer's Disease Progression Prediction
- Blueberry supplementation improves memory in older adults. [europepmc]
- Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the national Alzheimer's coordinating center database. [europepmc]
- The association between a polygenic Alzheimer score and cortical thickness in clinically normal subjects. [europepmc]
- Progression of Alzheimer's disease as measured by Clinical Dementia Rating Sum of Boxes scores. [europepmc]
- Characterization of Mexican Americans with mild cognitive impairment and Alzheimer's disease. [europepmc]
- Risk factors for mild cognitive impairment among Mexican Americans. [europepmc]
- Body mass index, weight change, and clinical progression in mild cognitive impairment and Alzheimer disease. [europepmc]
- Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center. [europepmc]
- Hippocampal sclerosis of aging is a key Alzheimer's disease mimic: clinical-pathologic correlations and comparisons with both alzheimer's disease and non-tauopathic frontotemporal lobar degeneration. [europepmc]
- A Feasibility Study with Image-Based Rendered Virtual Reality in Patients with Mild Cognitive Impairment and Dementia. [europepmc]
- Monoaminergic neuropathology in Alzheimer's disease. [europepmc]
- Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels. [europepmc]
- Distinct Subtypes of Behavioral Variant Frontotemporal Dementia Based on Patterns of Network Degeneration. [europepmc]
- Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers. [europepmc]
- Neuropathological diagnoses and clinical correlates in older adults in Brazil: A cross-sectional study. [europepmc]
- Neuropathologic Correlates of Psychiatric Symptoms in Alzheimer's Disease. [europepmc]
- Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE). [europepmc]
- Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype. [europepmc]
- The Health & Aging Brain among Latino Elders (HABLE) study methods and participant characteristics. [europepmc]
- Locus coeruleus integrity is related to tau burden and memory loss in autosomal-dominant Alzheimer's disease. [europepmc]
- Medical comorbidities and ethnicity impact plasma Alzheimer's disease biomarkers: Important considerations for clinical trials and practice. [europepmc]
- Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US. [europepmc]
- Long-term prognosis and educational determinants of brain network decline in older adult individuals. [europepmc]
- Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials. [europepmc]
- Lecanemab: Appropriate Use Recommendations. [europepmc]
Related